Clinical Trial Update: XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update indicating that XL092 for locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Follicular Thyroid Carcinoma
• Oncocytic Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• XL092

Snippet

Sponsor: Northwestern University | Conditions: Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Status: RECRUITING